CD38 and hematopoietic and lymphoid cell neoplasm: Ongoing trials are evaluating its efficacy in combination with immune checkpoint inhibitors (NCT04381650) and monoclonal antibodies targeting CD38 and CD20 (NCT04776018, NCT04074330) for hematologic cancers.